抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 3195人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1853054, encodeId=3844185305414, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Neurology：口服抗凝剂和ADP抑制剂疗法对脑外伤短期疗效的影响, objectType=article, longId=739325, objectId=355de3932588, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=355de3932588, replyNumber=0, likeNumber=0, createdTime=2023-06-20, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=355de3932588, moduleTitle=Neurology：口服抗凝剂和ADP抑制剂疗法对脑外伤短期疗效的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=355de3932588)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852930, encodeId=9db71852930b2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, objectType=article, longId=302295, objectId=5d50302295d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d50302295d1, replyNumber=0, likeNumber=112, createdTime=2022-04-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d50302295d1, moduleTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d50302295d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853039, encodeId=d07b1853039b8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=A&R：核输出的小分子抑制剂通过调节浆细胞生成和存活来改善狼疮, objectType=article, longId=736686, objectId=6c3ae36686fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c3ae36686fc, replyNumber=0, likeNumber=93, createdTime=2022-10-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c3ae36686fc, moduleTitle=A&R：核输出的小分子抑制剂通过调节浆细胞生成和存活来改善狼疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c3ae36686fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852846, encodeId=b2601852846e6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Haemophilia：使用与不使用 FVIII 抑制剂的重度 A 型血友病儿童患者中 emicizumab 预防的耐受性和安全性的真实世界经验, objectType=article, longId=292247, objectId=bce929224e89, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bce929224e89, replyNumber=0, likeNumber=80, createdTime=2022-02-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bce929224e89, moduleTitle=Haemophilia：使用与不使用 FVIII 抑制剂的重度 A 型血友病儿童患者中 emicizumab 预防的耐受性和安全性的真实世界经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bce929224e89)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852987, encodeId=4a45185298e45, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=突破血脑屏障，纳米颗粒携带抑制剂激活免疫系统，智取脑肿瘤，还能防复发, objectType=article, longId=728345, objectId=8747e283452c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8747e283452c, replyNumber=0, likeNumber=100, createdTime=2022-10-25, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8747e283452c, moduleTitle=突破血脑屏障，纳米颗粒携带抑制剂激活免疫系统，智取脑肿瘤，还能防复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8747e283452c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853035, encodeId=7c551853035bf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, objectType=article, longId=736572, objectId=7caae365721d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7caae365721d, replyNumber=0, likeNumber=150, createdTime=2023-07-19, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7caae365721d, moduleTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7caae365721d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852937, encodeId=4da1185293e66, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet：新型XIa抑制剂asundexian比阿哌沙班在心房颤动患者中更加安全, objectType=article, longId=723749, objectId=0e27e237490e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e27e237490e, replyNumber=0, likeNumber=67, createdTime=2022-11-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e27e237490e, moduleTitle=Lancet：新型XIa抑制剂asundexian比阿哌沙班在心房颤动患者中更加安全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e27e237490e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853010, encodeId=86811853010d0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ARD：IL-12/23通路抑制剂优特克单抗或TNFi 治疗银屑病关节炎患者的持久性和有效性相当, objectType=article, longId=730741, objectId=13a2e30741f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13a2e30741f5, replyNumber=0, likeNumber=73, createdTime=2023-01-20, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13a2e30741f5, moduleTitle=ARD：IL-12/23通路抑制剂优特克单抗或TNFi 治疗银屑病关节炎患者的持久性和有效性相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13a2e30741f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853055, encodeId=50381853055b1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Pharmacol Ther：血管紧张素转换酶抑制剂与胰岛素促泌剂同时使用与严重低血糖的风险, objectType=article, longId=739474, objectId=f928e39474c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f928e39474c7, replyNumber=0, likeNumber=89, createdTime=2023-03-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f928e39474c7, moduleTitle=Clin Pharmacol Ther：血管紧张素转换酶抑制剂与胰岛素促泌剂同时使用与严重低血糖的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f928e39474c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853047, encodeId=30dd185304ed6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=二肽基肽酶-4抑制剂与两种磺脲类药物的联合使用有助于胰岛β细胞数的正常化, objectType=article, longId=737058, objectId=6fece3705883, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fece3705883, replyNumber=0, likeNumber=69, createdTime=2022-09-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fece3705883, moduleTitle=二肽基肽酶-4抑制剂与两种磺脲类药物的联合使用有助于胰岛β细胞数的正常化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fece3705883)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852861, encodeId=f7ae18528617d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Ann Intern Med：接受肿瘤坏死因子抑制剂治疗的患者接种水痘-带状疱疹活疫苗的安全性和免疫学效果, objectType=article, longId=293604, objectId=1af629360491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1af629360491, replyNumber=0, likeNumber=77, createdTime=2022-03-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1af629360491, moduleTitle=Ann Intern Med：接受肿瘤坏死因子抑制剂治疗的患者接种水痘-带状疱疹活疫苗的安全性和免疫学效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1af629360491)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853056, encodeId=02041853056e7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, objectType=article, longId=739436, objectId=f1a5e39436f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1a5e39436f8, replyNumber=0, likeNumber=77, createdTime=2022-10-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1a5e39436f8, moduleTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1a5e39436f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852935, encodeId=c64d1852935c7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet：房颤患者采用新型FXIa小分子抑制剂Asundexian预防卒中的效果和安全性, objectType=article, longId=723521, objectId=25a3e23521c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25a3e23521c8, replyNumber=0, likeNumber=73, createdTime=2022-06-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25a3e23521c8, moduleTitle=Lancet：房颤患者采用新型FXIa小分子抑制剂Asundexian预防卒中的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25a3e23521c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852829, encodeId=7a9218528290a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：PARP抑制剂Pamiparib单药治疗铂敏感/耐药性卵巢癌的疗效, objectType=article, longId=221549, objectId=315622154982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=315622154982, replyNumber=0, likeNumber=90, createdTime=2022-09-30, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=315622154982, moduleTitle=Clin Cancer Res：PARP抑制剂Pamiparib单药治疗铂敏感/耐药性卵巢癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=315622154982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852902, encodeId=2b661852902d3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=风湿病必备的免疫抑制剂，怎么选择？教你一文看懂！, objectType=article, longId=300292, objectId=59a53002925e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59a53002925e, replyNumber=0, likeNumber=92, createdTime=2022-11-17, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59a53002925e, moduleTitle=风湿病必备的免疫抑制剂，怎么选择？教你一文看懂！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59a53002925e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852819, encodeId=210b1852819e1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Thorac Cancer：真实世界中中国非小细胞肺癌（NSCLC）伴有脑转移（BM）患者使用免疫检查点抑制剂（ICIs）的疗效, objectType=article, longId=220996, objectId=8ab722099677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ab722099677, replyNumber=0, likeNumber=96, createdTime=2022-01-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ab722099677, moduleTitle=Thorac Cancer：真实世界中中国非小细胞肺癌（NSCLC）伴有脑转移（BM）患者使用免疫检查点抑制剂（ICIs）的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ab722099677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852990, encodeId=783e185299006, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素, objectType=article, longId=728275, objectId=a347e2827567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a347e2827567, replyNumber=0, likeNumber=69, createdTime=2022-08-16, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a347e2827567, moduleTitle=ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a347e2827567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852955, encodeId=3cd21852955af, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=辉瑞第三代 ALK 抑制剂洛拉替尼（即劳拉替尼）在国内获批上市, objectType=article, longId=725779, objectId=c4c1e2577962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4c1e2577962, replyNumber=0, likeNumber=79, createdTime=2023-03-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4c1e2577962, moduleTitle=辉瑞第三代 ALK 抑制剂洛拉替尼（即劳拉替尼）在国内获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4c1e2577962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852969, encodeId=40831852969a5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=AJH：使用基于布鲁顿酪氨酸激酶抑制剂的一线疗法治疗TP53改变的 CLL：回顾性分析, objectType=article, longId=727113, objectId=2ccae2711328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ccae2711328, replyNumber=0, likeNumber=70, createdTime=2022-08-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ccae2711328, moduleTitle=AJH：使用基于布鲁顿酪氨酸激酶抑制剂的一线疗法治疗TP53改变的 CLL：回顾性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ccae2711328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853026, encodeId=630418530260c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Rheumatology：Janus激酶抑制剂和新型活动性疾病生物标记物在青少年皮肌炎中的长期随访结果, objectType=article, longId=734175, objectId=c505e341758a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c505e341758a, replyNumber=0, likeNumber=83, createdTime=2023-05-25, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c505e341758a, moduleTitle=Rheumatology：Janus激酶抑制剂和新型活动性疾病生物标记物在青少年皮肌炎中的长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c505e341758a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Neurology：口服抗凝剂和ADP抑制剂疗法对脑外伤短期疗效的影响

2023-06-20

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS

2022-04-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

A&R：核输出的小分子抑制剂通过调节浆细胞生成和存活来改善狼疮

2022-10-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Haemophilia：使用与不使用 FVIII 抑制剂的重度 A 型血友病儿童患者中 emicizumab 预防的耐受性和安全性的真实世界经验

2022-02-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

突破血脑屏障，纳米颗粒携带抑制剂激活免疫系统，智取脑肿瘤，还能防复发

2022-10-25

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较

2023-07-19

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet：新型XIa抑制剂asundexian比阿哌沙班在心房颤动患者中更加安全

2022-11-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ARD：IL-12/23通路抑制剂优特克单抗或TNFi 治疗银屑病关节炎患者的持久性和有效性相当

2023-01-20

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Pharmacol Ther：血管紧张素转换酶抑制剂与胰岛素促泌剂同时使用与严重低血糖的风险

2023-03-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

二肽基肽酶-4抑制剂与两种磺脲类药物的联合使用有助于胰岛β细胞数的正常化

2022-09-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Ann Intern Med：接受肿瘤坏死因子抑制剂治疗的患者接种水痘-带状疱疹活疫苗的安全性和免疫学效果

2022-03-13

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性

2022-10-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet：房颤患者采用新型FXIa小分子抑制剂Asundexian预防卒中的效果和安全性

2022-06-10

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：PARP抑制剂Pamiparib单药治疗铂敏感/耐药性卵巢癌的疗效

2022-09-30

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

风湿病必备的免疫抑制剂，怎么选择？教你一文看懂！

2022-11-17

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Thorac Cancer：真实世界中中国非小细胞肺癌（NSCLC）伴有脑转移（BM）患者使用免疫检查点抑制剂（ICIs）的疗效

2022-01-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素

2022-08-16

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

辉瑞第三代 ALK 抑制剂洛拉替尼（即劳拉替尼）在国内获批上市

2023-03-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

AJH：使用基于布鲁顿酪氨酸激酶抑制剂的一线疗法治疗TP53改变的 CLL：回顾性分析

2022-08-13

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Rheumatology：Janus激酶抑制剂和新型活动性疾病生物标记物在青少年皮肌炎中的长期随访结果

2023-05-25

科室
- - 订阅+
  - 更多科室
工具
服务